Co-Authors
This is a "connection" page, showing publications co-authored by AYSEGUL A SAHIN and LEI HUO.
Connection Strength
1.720
-
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
Score: 0.228
-
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
Score: 0.227
-
Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit. Semin Diagn Pathol. 2022 Sep; 39(5):313-321.
Score: 0.209
-
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
Score: 0.207
-
Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol. 2011 Apr; 15(2):84-92.
Score: 0.095
-
Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755.
Score: 0.062
-
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):236.
Score: 0.061
-
Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma. Clin Breast Cancer. 2024 Jun; 24(4):e310-e318.
Score: 0.059
-
TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med. 2024 Feb 01; 148(2):200-205.
Score: 0.059
-
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma. Cancers (Basel). 2023 Apr 28; 15(9).
Score: 0.056
-
Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated? Clin Breast Cancer. 2023 06; 23(4):415-422.
Score: 0.055
-
SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol. 2023 02; 36(2):100001.
Score: 0.055
-
Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022 07; 125:59-67.
Score: 0.052
-
TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2022 07; 125:97-107.
Score: 0.052
-
Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80.
Score: 0.051
-
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021 04; 34(4):710-719.
Score: 0.047
-
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.
Score: 0.036
-
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017 01; 161(2):279-287.
Score: 0.036
-
Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15.
Score: 0.025
-
Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77.
Score: 0.024
-
Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163.
Score: 0.022